

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. **(Currently Amended)** A method of treating an inflammatory disorder in a patient comprising~~reducing inflammation in a patient, comprising: identifying a patient suffering from or at risk for inflammation; and~~

administering to [[the]]a patient suffering from an inflammatory disorder at least one treatment selected from the group consisting of: inducing ferritin in the patient; expressing ferritin in the patient; and administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin to the patient, in an amount sufficient to treat the inflammatory disorder;

wherein the inflammatory disorder is selected from the group consisting of asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive pulmonary disease, primary pulmonary hypertension, chronic pulmonary emphysema, congestive heart failure, peripheral vascular disease, stroke, heart attacks, glomerulonephritis, conditions involving inflammation of the kidney, lung, liver, spleen, brain and/or skin, infection of the genitourinary tract, viral and toxic hepatitis, cirrhosis, ileus, necrotizing enterocolitis, specific and non-specific inflammatory bowel disease, rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, hemorrhagic, septic, or anaphylactic shock, amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, Crohn's disease and an inflammatory condition localized in the gastrointestinal tract~~reduce inflammation.~~

2. **(Original)** The method of claim 1, wherein the treatment is inducing ferritin in the patient.

3. **(Original)** The method of claim 1, wherein the treatment is expressing ferritin in the patient.

4. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising HO-1 to the patient.

5. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising biliverdin to the patient.

6. **(Original)** The method of claim 5, wherein the pharmaceutical composition is administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.

7. **(Currently Amended)** The method of claim 6, wherein the inflammatory disorder ~~is inflammation is associated with~~ ulcerative colitis.

8. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising bilirubin to the patient.

9. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising ferritin to the patient.

10. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.

11. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising iron dextran to the patient.

12. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising apoferritin to the patient.

13. **(Original)** The method of claim 2, wherein the ferritin is induced by administering iron to the patient.

14. **(Currently Amended)** The method of claim 1, wherein the ~~inflammation is associated with a condition~~ inflammatory disorder is selected from the group consisting of: asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive pulmonary disease primary pulmonary hypertension, chronic pulmonary emphysema, congestive heart failure, peripheral vascular disease, stroke, ~~atherosclerosis~~,

ischemia-reperfusion injury, heart attacks, glomerulonephritis, conditions involving inflammation of the kidney, infection of the genitourinary tract, viral and toxic hepatitis, cirrhosis, ileus, necrotizing enterocolitis, specific and non-specific inflammatory bowel disease, rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, and hemorrhagic, septic, or anaphylactic shock.

15. **(Currently Amended)** The method of claim 1, wherein the inflammatory disorder is a condition involving inflammation is inflammation of the ~~heart~~, lung, liver, spleen, brain, skin, and/or kidney.

16. **(Currently Amended)** The method of claim 1, wherein the inflammatory disorder is inflammation is an inflammatory condition localized in the gastrointestinal tract.

17. **(Currently Amended)** The method of claim [[16]]1, wherein the inflammatory disorder condition is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

18. **(Currently Amended)** The method of claim [[17]]1, wherein the inflammatory disorder condition is ulcerative colitis.

19. **(Original)** The method of claim 1, further comprising the step of administering to the patient at least one treatment selected from the group consisting of: inducing HO-1 in the patient; expressing HO-1 in the patient; and administering a pharmaceutical composition comprising carbon monoxide to the patient.

20. **(Currently Amended)** The method of claim 1, further comprising the steps of inducing [[HOI]]HO-1 in the patient, and administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-62. **(Canceled)**